



## SETTING THE NEW STANDARD IN SKIN SURGERY WITH ADVANCED TISSUE THERAPEUTICS

- denovoSkin™ safely restores skin function in patients that need skin surgery: from burns to reconstructive/aesthetics → VS Standard of Care (SoC) it drastically spares donor site & improves scar quality & functionality long term
- Based on clinical data from our >65 patients treated to date, the favourable competitive landscape, & on our first-in-class automated production platform we are at the forefront of a revolution in skin grafting globally

BELOW, IN PICTURES: denovoSkin™ (personalized tissue therapy); the current SoC in skin surgery (autografting); VITICELL® (our skin pigmentation device); our pioneer fully automated cell extraction module and tissue therapy production module.




PHASE 1 CLINICAL TRIAL – 5Y FOLLOW UP



PHASE 2 CLINICAL TRIAL – denovoSkin™ vs SoC



PHASE 2 CLINICAL TRIAL – denovoSkin™ vs SoC



SKIN PIGMENTATION RESTORATION



TISSUE CELL EXTRACTION AUTOMATION



TISSUE THERAPY PRODUCTION AUTOMATION

### WHAT KEY OPINION LEADERS SAY ABOUT denovoSkin™

[...] made the difference between a primarily palliative therapy and a curative approach. Functional results are impressive.  
*Prof. Dr. med. Thomas Kremer, September 2022, Klinikum St. Georg, Leipzig, Germany*

[...] the skin quality is just like the patient's own: supple, soft and mobile. Patient hospitalized at least 1-2 months shorter.  
*Prof. Dr. med. Catherine DeBlacam, September 2022, Children's Health Ireland at Crumlin, Dublin, Ireland*

[...] results remained consistent, showing natural/robust surfaces, near normal elasticity, and no hyper-trophic scarring.  
*Prof. Dr. med. Clemens Schiestl, September 2021, University Children's Hospital Zurich, Switzerland*

[...] this was a desperate neonatal case, the results are simply incredible to believe.  
*Prof. Dr. med. Marcello Zamparelli, March 2022, SANTOBONO Hospital, Napoli, Italy*



## INVESTMENT HIGHLIGHTS

- Only **TECHBIO**, late-stage clinical company (est. 2017), replacing current standard of care in skin surgery
- **1st PERSONALIZED TISSUE THERAPEUTICS** for a broad range of indications: from severe burns all the way to aesthetics

- Fastest-growing sector among advanced therapies (>US\$27bn market) with new tissue products becoming integral part of body restoration procedures (e.g. Humacyte approved 2024)
- High demand for skin tissue therapeutics with superior functional and cosmetic outcome in a very liquid, growing skin surgery market
- Recent validation of the skin surgery market with Coloplast's acquisition of Kerecis (US\$1.3bn) in 2023
- CUTISS' entry market (burns, orphan/rare) with highest unmet need, life-saving label, attractive pricing and accessible reimbursement schemes
- Rapid indication expansion into reconstructive, plastic and aesthetics
- Portfolio expansion & Space Research via French Subsidiary

- US\$2.1bn revenue in 2032 – 10% market share US/EU
- Long term safety and efficacy readout in burns and reconstructive (Phase 1 & 2); Phase 3 recruiting in EU
- Proprietary production automation modules for scalability
- Own labs and GMP facility fully certified by Swissmedic.
- Integrated advanced AI across multiple departments to foster efficiency e.g. real time GMP monitoring
- Senior management team with superior expertise, industry experience in tissue therapeutics and wound management from Smith&Nephew, Organogenesis, L'Oreal and others.
- World-class advisors and board members
- Go-to-market strategy supported by granular forecasts
- Wide recognition via multiple awards and media presence

- Liquidity event planned in the next 2-3 years
- Over US\$67m raised in financing rounds seed-to-B
- **Series C open** for US\$60m to pave the way to commercialization:  
→US\$25m secured in a first-closing in 2024

US\$=CHF

## OUR FOCUS AREAS

**SKIN TISSUE THERAPEUTICS-** The current Standard of Care (SoC) in burn and reconstructive surgery (trauma, scar, cancer resection etc.) is the autografting of thin skin sheets harvested from patient's own healthy sites. SoC is scarce, costly and leads to debilitating scarring that needs high maintenance. **denovoSkin™**, is our personalized skin tissue therapeutic to replace autografting, bio-engineered in 3-4 weeks in large quantities using a stamp-sized sample of patient's own skin. Our clinical data proves long-term safety and efficacy vs SoC, showing significant improvement in patients' quality of life by minimizing scarring, thus also promising to lower total healthcare costs. Burns, planned entry market, are classified as a rare (orphan) in EU-US, with fast-track options towards market authorization.

**AUTOMATED PRODUCTION PLATFORM-** To secure scale-up, allow decentralization and achieve relevant cost reduction for the in-house manufacturing of **denovoSkin™**, CUTISS develops first-in-class automated bio-reactors for tissue cell extraction and tissue therapy production. This pioneering, proprietary platform could be used beyond skin for the next-priority human tissues (muscle, gums, etc) and beyond healthcare in deeptech.

**ADVANCED DERMATOLOGY** - Skin color restoration in vitiligo, dyspigmented scars and grafted **denovoSkin™**, with innovative medical devices for personalized cell therapy at point-of-care.

### KEY CATALYSTS 2025


- Recruiting for Phase 3
- Readiness for Orphan Market
- Advancing automation industrialization
- Readiness for VITICELL® launch

## CURRENT PRODUCT PIPELINE

**denovoSkin™** - is advanced tissue therapy on demand. Same as one's own skin, it is composed of an epidermis (top, protective layer=life) and a dermis (the structural, below layer=quality of life). Key differences from the SoC:

	Autografting (SoC)	denovoSkin™
Scar minimization	No	Yes
Expansion factor of patient's skin sample	<9x	>100x

**VITICELL®** – acquired under a global, exclusive commercialization license from IBSA Pharma – has been CE-marked for the cell therapy treatment of vitiligo and dyspigmented burn scars at point of care.





## EXTREMELY FAVOURABLE COMPETITIVE LANDSCAPE

**denovoSkin™** has no direct competitor on the market. It is the only personalized skin tissue therapy to fully replace autografting, drastically minimize scarring and significantly spare healthy patient skin. In the very liquid skin surgery market, denovoSkin™ pricing is not disruptive and it offers strong healthcare savings, attractive unit economics and accessible reimbursement options. **Today**, in acute/elective skin surgery, wound beds are initially prepared for autografting by the application of e.g. allografts, smart matrices (e.g. PolyNovo), xenografts (e.g. Keretic) or dermal templates (e.g. Integra). Weeks later, once the wounds are ready, surgeons proceed with autografting. In the US, autografting can also be co-adjuvated by cell sprays (e.g. Avita) or epidermal sheets (e.g. Vericel). Wound dressing materials are then used to protect the grafted areas and a plethora of products are used to maintain the scars.

**VITICELL®**: is an accessible cell therapy device for skin color restoration at point-of-care. The closest to it is Avita's RECELL® (US only)

**Automated tissue production platform.** CUTISS' proprietary platform is the only automated, complete solution for fully closed production of personalized skin tissue. Other devices are on the market: printers (e.g. Rokit, etc.) or cell expanders (e.g. Terumo, etc.).

## REGULATORY PATHWAY - HIGHLIGHTS

**denovoSkin™**: advanced therapy tissue engineered (ATMP-TE, EMA (2022) and is a biologic/BLA in US. denovoSkin™ has been granted ORPHAN DRUG DESIGNATION (ODD) for 2<sup>nd</sup>/3<sup>rd</sup> degree burns by EMA/FDA/Swissmedic (2015). **CUTISS' automated modules** will be integrated into the GMP manufacturing post denovoSkin™'s market authorization as a process variation. **VITICELL®**: already CE-marked under MDD, now in transition to MDR at CUTISS.

## EXCELLENT denovoSkin™ CLINICAL DOSSIER

More than 65 patients treated since 2014. **Long-term safety and efficacy** (Phase 1 and 2) successful readout in **BURNS and RECONSTRUCTIVE**. **Confirmatory trials recruiting** in EU (Phase 3, last trial). Eight (8) compassionate patients treated for massive burns or complex reconstruction EU/US. Several reports published.

## CLEAR GO-TO-MARKET STRATEGY

**denovoSkin™**: produced in-house (first manually, then automatically), in CUTISS' regional hubs. We first target the highly accessible, orphan burn market with direct sales, an attractive pricing strategy and very favorable reimbursement schemes. Reconstructive/aesthetic surgery markets will follow right after.

**VITICELL®**: sold via distributors in multiple regions.

## FAR BEYOND

CUTISS' know-how, platform and IP can be exploited:

- far beyond skin for e.g. gums, mucosa, cornea, muscle etc.
- far beyond earth, with first-in-class space research programs on healing and ageing. First data available in Q2 2025.
- far beyond healthcare, with deeptech automated tissue generation programs

CUTISS INNOVATION in France is active on all those areas.

## CURRENT CAP TABLE

Experienced investors, family offices, HNWI, foundations, banks, such as: Giammaria Giuliani of Giuliani Pharma, Wyss Foundation, ZKB, Yellowstone Holding, UZH LF fund, Lichtsteiner foundation, Innosuisse, EU commission. Largest shareholder: ca. 10%.

## PIONEERING AUTOMATION PLATFORM

CUTISS has developed automated modules and processes to manufacture large quantities of denovoSkin™ via 1. tissue cell extraction, 2. cell expansion, 3. tissue therapy production in a fully closed system, disposal based. Developed with leading partners, the modules are active in the R&D laboratory and are now entering the next development phase towards clinical use readiness and industrialization.

## INTELLECTUAL PROPERTY

**2x** Patents exclusively licenced by University of Zurich (CUTISS is a Spin-Off); granted EU/US/others (2013/2014). **1x** patent owned by CUTISS; granted US (2021). **6x** Patents owned by CUTISS; national phase (2019/2022). **Trade secret** of production process. **Market exclusivity** 7-10 years in US-EU respectively.

## OUR PARTNERS



## SERIES C - PAVING THE WAY TO MARKET

To date, >US\$67M was raised (dilutive and non). Post positive efficacy results in burns, a Series C for US\$40-60M is now open (minimum ticket size US\$250k). **US\$25M secured in first closing**. The round is co-led by the family office of Giammaria Giuliani (existing investor) and a US family (new). A liquidity event is expected in the next 2-3 years. The Series C proceeds will be used to:

- complete the clinical validation of denovoSkin™;
- advance preparation for the Market Authorization (incl. fast track) dossiers for Swissmedic, EMA and FDA;
- bring the automated tissue engineering modules to clinical readiness and expand manufacturing capacity;
- commercially launch VITICELL®;
- grow the management, team and board expertise in areas such as commercial, medical and financial.





Outstanding expertise at executive and advisory level. Extensive international experience and network in skin engineering and skin tissue therapy, from bench-2-bed-2-market, manufacturing, engineering. Experience in leading SME and large enterprises like MODEX (CH), L'OREAL (FR, China), HEALTHPOINT (US), SMITH&NEPHEW (US), A-STAR (Singapore), ORGANOGENESIS (US) etc. The company operates with a team of ~50 employees, out of two locations (Switzerland - HQ and France – fully owned subsidiary focused on innovation and portfolio expansion).

## EXECUTIVE TEAM



**D. MARINO**, CEO  
Co-founder

**ETH zürich**



**K. MUJYNYA**, COO



UNIL | Université de Lausanne



Head of Asian Skin Bank  
Developer of Epidex



**V. RONFARD**, CIO



L'ORÉAL



Empowering Healing

Developer of Apligraf®  
Developer of Skin models

## MEDICAL ADVISORS & INTERNATIONAL KOL, AMONG OTHERS:



**M. MEULI**

Chairman/co-founder  
Pediatric/fetal surgery



**L. TEOT**

Medical advisor  
Skin surgery and  
scar management



**S. AKITA**

Medical Advisor  
Burn and plastic  
surgery



**J. GOVERMAN**

Medical Advisor  
Burn and reconstructive  
surgery



**T. PASSERON**

Medical advisor  
Vitiligo/dermatology

## KEY INVESTORS & BOARD MEMBERS:



**GIAMMARIA GIULIANI**

Largest shareholder  
BoD of Giuliani Pharma,  
HBM, Royalty Pharma.  
Rothschild&Co  
Supervisory Board.



**HANSJÖRG WYSS**

Founder of Synthes  
USA sold for \$20bn  
to J&J. Founder of  
Wyss Institute in  
Boston, Geneva  
and Zurich.



**GERARD BER**

Co-Founder, COO  
and Board Member  
of AAA sold for \$4bn  
to Novartis in 2018.



Leading your legacy



UZH Life Sciences Fund



**LICHTSTEINER FOUNDATION**



Yellowstone Holding AG

